

Federica Fioroni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4710042/publications.pdf>

Version: 2024-02-01

28
papers

602
citations

687363

13
h-index

610901

24
g-index

31
all docs

31
docs citations

31
times ranked

1108
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive and Prognostic Role of Pre-Therapy and Interim ⁶⁸ Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT. <i>Cancers</i> , 2022, 14, 592.	3.7	12
2	How direct measurements on worker eyes with Scheimpflug camera can affect lens dose conversion coefficients in interventional radiology. <i>Journal of Radiological Protection</i> , 2021, 41, .	1.1	1
3	Texture analysis and multiple-instance learning for the classification of malignant lymphomas. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 185, 105153.	4.7	24
4	Comparison of different calculation techniques for absorbed dose assessment in patient specific peptide receptor radionuclide therapy. <i>PLoS ONE</i> , 2020, 15, e0236466.	2.5	9
5	DNA damage in lens epithelial cells exposed to occupationally-relevant X-ray doses and role in cataract formation. <i>Scientific Reports</i> , 2020, 10, 21693.	3.3	5
6	⁶⁸ Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients. <i>Frontiers in Medicine</i> , 2020, 7, 601853.	2.6	11
7	Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. <i>EJNMMI Physics</i> , 2020, 7, 63.	2.7	21
8	Partial volume effect of SPECT images in PRRT with ¹⁷⁷ Lu labelled somatostatin analogues: A practical solution. <i>Physica Medica</i> , 2019, 57, 153-159.	0.7	14
9	Effect of image registration on 3D absorbed dose calculations in ¹⁷⁷ Lu-DOTATOC peptide receptor radionuclide therapy. <i>Physica Medica</i> , 2018, 45, 177-185.	0.7	7
10	Added diagnostic value of respiratory-gated ^{4D} ¹⁸ F-FDG PET/CT in the detection of liver lesions: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 102-109.	6.4	22
11	Radiomic Profiling of Head and Neck Cancer: ¹⁸ F-FDG PET Texture Analysis as Predictor of Patient Survival. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-8.	0.8	36
12	¹⁸ F-fluorodeoxyglucose positron emission tomographic scan in solid-type p-stage-I pulmonary adenocarcinomas: what can produce false-negative results? <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, ezw394.	1.4	6
13	^{90}Y and ^{177}Lu -DOTA-Bioconjugates	0.8	16
14	Therapeutic schemes in ¹⁷⁷ Lu and ^{90Y} -PRRT: radiobiological considerations. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 216-231.	0.7	15
15	Skin dose saving of the staff in ^{90Y} / ¹⁷⁷ Lu peptide receptor radionuclide therapy with the automatic dose dispenser. <i>Nuclear Medicine Communications</i> , 2016, 37, 1046-1052.	1.1	5
16	The ⁶⁸ Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq0 0 0, r gBT /Overlock 10 Tf	0.9	20
17	The Italian multicentre dosimetric study for lesion dosimetry in ²²³ Ra therapy of bone metastases: Calibration protocol of gamma cameras and patient eligibility criteria. <i>Physica Medica</i> , 2016, 32, 1731-1737.	0.7	22
18	Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with ^{125}I Decay. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1501-1506.	5.0	26

#	ARTICLE	IF	CITATIONS
19	Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients. <i>Thyroid</i> , 2014, 24, 715-726.	4.5	68
20	Radiation protection procedures in ¹³¹ I treatments for thyroid cancer in patients requiring hemodialysis. <i>Nuclear Medicine Communications</i> , 2014, 35, 626-630.	1.1	2
21	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1113-1122.	6.4	152
22	Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1381-1390.	6.4	50
23	COMPARISON OF TWO DIFFERENT TYPES OF LiF:Mg,Cu,P THERMOLUMINESCENT DOSIMETERS FOR DETECTION OF BETA RAYS (BETA-TLDS) FROM ⁹⁰ Sr/ ⁹⁰ Y, ⁸⁵ Kr AND ¹⁴⁷ Pm SOURCES. <i>Health Physics</i> , 2011, 100, 515-522.	0.5	10
24	Personnel exposure in labelling and administration of ¹⁷⁷ Lu-DOTA-D-Phe ¹ -Tyr ³ -octreotide. <i>Nuclear Medicine Communications</i> , 2011, 32, 947-953.	1.1	10
25	PET systems: the value of added length. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1629-1632.	6.4	12
26	Radiation protection in ⁹⁰ Y-labelled DOTA-D-Phe ¹ -Tyr ³ -octreotide preparations. <i>Nuclear Medicine Communications</i> , 2009, 30, 176-182.	1.1	18
27	⁴ D PET data sorting into different number of phases: a NEMA IQ phantom study. <i>Journal of Applied Clinical Medical Physics</i> , 2009, 10, 220-231.	1.9	8
28	Use of Positron Emission Tomography for Target Volume Definition. <i>Current Radiopharmaceuticals</i> , 2009, 2, 144-148.	0.8	0